Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Precigen ( (PGEN) ) has provided an announcement.
Precigen has announced a private placement of $79.0 million through the sale of its 8.00% Series A Convertible Perpetual Preferred Stock and warrants to purchase common stock. The proceeds from this financing, which includes investments from Patient Capital Management and others, are expected to extend Precigen’s cash runway into 2026, supporting the anticipated commercial launch of PRGN-2012 in 2025.
More about Precigen
Precigen is a biopharmaceutical company focused on developing innovative gene and cell therapies, specifically targeting immuno-oncology, autoimmune disorders, and infectious diseases. The company aims to create affordable biotherapeutics by advancing a pipeline of differentiated therapies towards clinical proof-of-concept and commercialization.
YTD Price Performance: -45.82%
Average Trading Volume: 915,136
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $212.7M
See more insights into PGEN stock on TipRanks’ Stock Analysis page.
